Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remicade in Chronic Beryllium Disease
NCT00111917Phase 2Terminated
- Start
- Feb 2005
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of infliximab in Chronic beryllium disease (CBD). Primary endpoint: Alveolar-arterial Gradient at End Exercise at 28 weeks. Started Feb 2005; status: terminated.
02
Drugs
infliximab
03
Conditions
Chronic beryllium disease (CBD)
Beyond the preview
Go deeper on NCT00111917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111917.